Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central nervous process, conolidine modulates alternate molecular targets. A Science Developments study located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabilit... https://derrickm283wlq8.bloguerosa.com/profile